SCHEMBL10028048

SCHEMBL10028048

Cc1ccc(-c2ccccc2C(F)(F)F)o1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.51
LMNA P02545 6/20 0.49
ALDH1A1 P00352 5/20 0.49
NPFFR1 Q9GZQ6 2/20 0.49
NPFFR2 Q9Y5X5 2/20 0.49
POLB P06746 2/20 0.49
SLC9A1 P19634 1/20 0.49
GAA P10253 1/20 0.49
HSD11B1 P28845 2/20 0.47
MAPT P10636 3/20 0.47
HPGD P15428 2/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
TDP1 Q9NUW8 3/20 0.46
KDM4E B2RXH2 3/20 0.45
TNFRSF1A P19438 2/20 0.44
PDE7A Q13946 1/20 0.42
PDE3A Q14432 1/20 0.42
PSMB8 P28062 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20821559 0.79 ADORA2A (0.38) SMN1; SMN2ALDH1A1SLC9A1GAAHSD11B1
SCHEMBL27591664 0.78 LMNA (0.49) SMN1; SMN2LMNAALDH1A1NPFFR1NPFFR2
SCHEMBL16316327 0.77 SMN1; SMN2 (0.48) SMN1; SMN2LMNAALDH1A1NPFFR1NPFFR2
SCHEMBL5544657 0.75 SMN1; SMN2 (0.49) SMN1; SMN2ALDH1A1POLBSLC9A1GAA
SCHEMBL12826605 0.74 ALDH1A1 (0.51) SMN1; SMN2LMNAALDH1A1NPFFR1NPFFR2
SCHEMBL2158430 0.74 NPFFR1 (0.59) SMN1; SMN2LMNAALDH1A1NPFFR1NPFFR2
SCHEMBL2557123 0.74 LMNA (0.49) SMN1; SMN2LMNAALDH1A1NPFFR1NPFFR2
SCHEMBL281711 0.74 ALDH1A1 (0.50) SMN1; SMN2LMNAALDH1A1NPFFR1NPFFR2
SCHEMBL10028052 0.74 ALDH1A1 (0.62) SMN1; SMN2ALDH1A1HSD11B1MAPTHPGD
SCHEMBL13941734 0.74 NPFFR1 (0.59) SMN1; SMN2LMNAALDH1A1NPFFR1NPFFR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120010259-A1 Methods of Treating an Overweight or Obese Subject ZAFGEN, INC. 2012-01-12 US disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010259-A1 Methods of Treating an Overweight or Obese Subject METAP2, METAP1, ACER2 SMN1; SMN2 1171/4885LMNA 4242/4885ALDH1A1 802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.